SARS-CoV-2 related pneumonia in an adult with cystic fibrosis: natural favourable clinical course or effective therapy?

Abstract

We report the case of a man affected by cystic fibrosis who developed a severe SARS-CoV-2 related pneumonia in March 2020. In addition to lopinavir/ritonavir and hydroxychloroquine, he was treated with two doses of tocilizumab, displaying a significant clinical improvement. This is the first case described in the literature of an adult patient affected by cystic fibrosis who received tocilizumab for COVID-19, with documented total recovery, also assessed by a spirometry.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.
Published
2020-12-23
Info
Issue
Section
COVID-19 - Collection of articles on the Coronavirus outbreak
Keywords:
COVID-19, tocilizumab, cystic fibrosis
Statistics
  • Abstract views: 273

  • PDF: 163
How to Cite
Giglia, M., Beci, G., Rosselli Del Turco, E., Guardigni, V., Amedeo, A., Cucchetto, G., Verucchi, G., Cipolli, M., Calza, L., & Viale, P. (2020). SARS-CoV-2 related pneumonia in an adult with cystic fibrosis: natural favourable clinical course or effective therapy?. Monaldi Archives for Chest Disease, 90(4). https://doi.org/10.4081/monaldi.2020.1579